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Abstract 22 
Rapid up regulation of interferon-β (IFN-β) expression following virus infection is essential 23 
to set up an efficient innate antiviral response. Biological roles related to the antiviral and 24 
immune response have also been associated to the constitutive production of IFN-β in naïve 25 
cells. However, mechanisms capable to modulate constitutive IFN-β expression in the 26 
absence of infection remain largely unknown. In this work we demonstrate that inhibition of 27 
kinase GSK-3 leads to the up-regulation of the constitutive level of IFN-β expression in non-28 
infected cells, provided that GSK-3 inhibition be correlated with binding of β-catenin to the 29 
IFN-β promoter. Under these conditions, IFN-β expression occurred through the T-cell factor 30 
(TCF) binding sites present on the IFN-β promoter, independently of IRF3. Enhancement of 31 
the constitutive level of IFN-β was per se capable to confer an efficient antiviral state to naïve 32 
cells and acted in synergy with virus infection to stimulate virus-induced IFN-β expression. 33 
Further emphasizing the role of β-catenin in the innate antiviral response, we show here that 34 
highly pathogenic Rift Valley fever virus (RVFV) targets the Wnt/β-catenin pathway and the 35 
formation of active TCF/β-catenin complexes at the transcriptional and protein level in 36 
RVFV-infected cells and mice.   37 
38 
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Introduction 39 
Production of interferon-β (IFN-β) plays a central role in the induction of the innate 40 
antiviral response (1,2). Rapid up-regulation of IFN-β gene expression occurs after 41 
recognition of viral nucleic acids by pattern recognition receptors (PRRs) either cytosolic 42 
such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated 43 
antigen 5 (MDA-5) or membrane-associated Toll-like receptors such as TLR3 (3). After 44 
sensing single or double stranded RNA of viral origin, these receptors activate signaling 45 
pathways implicating the phosphorylation and nuclear translocation of several transcription 46 
factors among which the interferon regulatory factor 3 (IRF3), rapidly leading downstream to 47 
a robust activation of the expression of IFN-β gene. After being secreted, IFN-β protein binds 48 
to the type I interferon receptor and triggers the JAK-STAT1/2 signal transduction pathway. 49 
This pathway leads to the activation and inhibition of the expression of a large set of genes 50 
that constitute the type I IFN response mounted to antagonize viral infection at different levels 51 
(4).  52 
Mice lacking IFN-β (5) or the subunit of the type I interferon receptor (6,7) are highly 53 
susceptible to viral infections. They succumb to sub-lethal doses of a variety of viruses thus 54 
confirming the main role of IFN-β in the establishment of an innate antiviral response. 55 
However, beyond the antiviral response, IFN-β affects a wide range of other biological 56 
functions for the most related to modulation of the immune (innate and adaptive) and 57 
inflammatory responses as well as to cell proliferation and differentiation. Even though IFN-β 58 
has been described of anti-inflammatory benefit, it has also been implicated in the 59 
development of several inflammatory and autoimmune diseases (8-10). Hence, the beneficial 60 
or detrimental outcome of IFN-β expression for the organism will depend on the timing, the 61 
kinetics and the amount of IFN-β being synthesized (11,12). If a marked activation of IFN-β 62 
gene expression is required to efficiently set up the appropriate response to an external 63 
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aggression such as virus infection, this response needs to be adjusted in order to limit its 64 
pathological side effects. 65 
As expected for a gene with pleiotropic functions, its transcriptional state is regulated 66 
at different levels. At the cellular level, only a stochastic fraction of the infected cells produce 67 
IFN-β (13,14) as a way to avoid an exacerbated and uncontrolled IFN response. At the 68 
nuclear level, one IFN-β allele localizes within interchromosomal regions rich in NF-κB 69 
DNA binding sites before and after infection (15) whereas the other allele localizes next to 70 
pericentromeric heterochromatin (PCH) clusters in the absence of infection and dissociates 71 
from PCH clusters during infection (16). The monoallelic characteristic of these particular 72 
subnuclear localizations suggests that a yet non-deciphered regulatory mechanism exists at 73 
the chromosome level. Finally, at the promoter level, the coordinated action of several 74 
transcription factors and chromatin remodeling complexes (17-21) regulate the IFN-β 75 
promoter transcriptional capacity. Among transcription factors, IRF3 plays an essential role 76 
during pathogen dependent activation of IFN-β gene expression in most cell types (22). 77 
Alongside with IRF3, are recruited over the promoter transcription factors such as NF-κB 78 
(15,23), ATF2/c-Jun and YY1 (20,24,25) that participate in the recruitment of chromatin 79 
remodeling complexes associated with histone acetyltransferase CBP. Some of these factors 80 
play dual roles, acting not only as activators but also as repressors of IFN-β expression. This 81 
is the case for NF-kB (26) and YY1 (27). Specially, YY1 participates in the transcriptional 82 
activation through recruitment of CBP and in the establishment of the repressive state of the 83 
IFN-β promoter through recruitment of co-repressor SAP30 (21) and association with 84 
pericentromeric heterochromatin (16).  85 
Even though the IFN-β gene has been considered as repressed in naïve cells, low 86 
levels of IFN-β have been detected in different types of non-infected cells in the central 87 
nervous system (28,29), splenocytes and mouse embryonic fibroblasts (MEFs) (30) implying 88 
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the existence of mechanisms capable to regulate the production of limited amounts of IFN-β 89 
in the absence of infection. Using anti-IFN-α/β antibodies, Haller et al. (31) evidenced a role 90 
of such IFN-β production with respect to the establishment of an active antiviral response. 91 
Using a similar strategy, Vogel and Fertsch (32) showed that the IFN-β production detected in 92 
non-infected cells had an autostimulatory role upon macrophage differentiation. More 93 
recently, results obtained with mice lacking either IFN-β or its receptor have confirmed the 94 
physiological role of such low amounts of IFN-β produced by non-infected animals in 95 
relation with several biological functions such as immune cell function, antiviral defense, 96 
bone remodeling and modulation of homeostatic balance (reviewed in 33). As in the case of 97 
virus-induced IFN-β production, deregulation of virus-independent IFN-β expression can lead 98 
to pathological effects. However, mechanisms capable to affect IFN-β expression in the 99 
absence of infection remain to be clarified. 100 
In the cytoplasm, β-catenin is found within a degradation complex associated with 101 
Adenomatous Polyposis Coli (APC), Axin and GSK-3 as well as CK1A Ser/Thr kinases that 102 
control the level of free β-catenin by a phosphorylation-dependent targeting of β-catenin 103 
towards proteasome degradation (34,35). Disruption of the degradation complex through 104 
inhibition of GSK-3 kinase leads to the increase of β-catenin and its subsequent nuclear 105 
accumulation. In the nucleus, β-catenin physically interacts with T-cell factor (TCF) to 106 
regulate the expression of target genes through the recruitment of a transcriptional activator 107 
complex containing B-Cell Lymphoma 9 (BCL9) protein and CBP over promoter regions 108 
carrying binding sites for TCF factors (36-38).  109 
With the goal to identify mechanisms susceptible to affect the level of IFN-β 110 
expression in the absence of infection, namely IRF3-NFκB-ATF2/cJUN-independent 111 
expression considered here as constitutive expression, we have questioned in this work the 112 
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capacity of nuclear β-catenin to regulate IFN-β expression, in naïve and infected cells, in 113 
association with the TCF family of transcription factors for which we show that DNA binding 114 
sites are present in the murine and human IFN-β promoter.  115 
We demonstrate here that LiCl treatment, a potential inhibitor of GSK-3, enhanced the 116 
constitutive level of IFN-β expression provided that it would lead to the interaction of β-117 
catenin with IFN-β promoter. While it has been previously reported that β-catenin would 118 
modulate IFN-β expression either positively (39-43) or negatively (44) through IRF3, our 119 
results uncover a new mechanism of up-regulation of the transcriptional capacity of the IFN-β 120 
promoter following LiCl treatment mediated by TCF/β-catenin complexes recruited over the 121 
IFN-β promoter region. Moreover, we show that the up-regulation of the constitutive level of 122 
IFN-β expression following LiCl treatment leads to the establishment of an efficient antiviral 123 
state protecting naïve cells against virus-induced cytopathic effect and acts in synergy with 124 
infection to increase IFN-β production. Further emphasizing the importance of TCF/β-catenin 125 
complex formation in the antiviral response, we show here that the pathogenicity induced by 126 
Rift Valley fever virus (RVFV) infection of cell cultures and mice was correlated with viral 127 
targeting of the TCF/β-catenin pathway at different levels.  128 
129 
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Materials and Methods 130 
Virus, Cells and Mice 131 
Stocks of RVFV ZH548 and RVFV ZH∆NSs were produced under BSL3 conditions 132 
by infecting Vero cells at m.o.i. of 10-3 and by harvesting the medium at 72 hr p.i. Murine 133 
fibroblastic L929 cell line and NDV infections were described previously (45). Murine 134 
hepatocyte AML12 cell line was from ATCC (ref. CRL-2254). For preparation of bone 135 
marrow-derived macrophages (BMDM) preparation, bone marrow from tibiae and femora of 136 
8-12 weeks B6 mices was flushed and cultured for 7 days in DMEM containing 10% heat-137 
inactivated fetal bovine serum, 100 U/ml penicillin/streptomycin, 2 mM glutamine and 10 138 
ng/ml murine M-CSF (Peprotech). Infection of mice was performed as previously described 139 
(46). When indicated, LiCl, iCRT3 (Sigma) or LiCl+iCRT3 were directly added to the culture 140 
medium.  141 
 142 
Antibodies 143 
Mouse anti-NSs and rabbit anti-N polyclonal antibodies were raised respectively 144 
against the entire NSs or N protein (47). Anti-β-catenin from BD Transduction laboratories 145 
(Cat#610154) was used for immunofluorescence, Western blot and gel retardation. Secondary 146 
antibodies used for immunofluorescence were Alexa 488 fluor-conjugated chicken anti-147 
mouse from Invitrogen (A21200) and Alexa 555 fluor-conjugated donkey anti-rabbit from 148 
Invitrogen (A31572). Secondary antibodies used for Western blot were ECL Mouse IgG, 149 
HRP-linked whole Ab (NA931) an ECL Rabbit IgG, HRP-linked whole Ab (NA934) from GE 150 
Healthecare Life Sciences.  151 
 152 
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Immunofluorescence 153 
For immunofluorescence, cells grown in 6-well plates on coverslips were fixed with 154 
4% formaldehyde in PBS for 15 minutes and permeabilized with 1% Triton X-100 in PBS for 155 
20 minutes. Then cells were incubated for 1 hour at room temperature with the corresponding 156 
primary antibodies diluted in PBS/BSA 5%. Cells were then washed with PBS and incubated 157 
for 1 hour at room temperature with corresponding secondary antibodies.   158 
 159 
Image acquisition and manipulation 160 
Samples were analyzed at room temperature by confocal laser scanning microscopy 161 
using a Zeiss LSM710 confocal system at the Service Commun de Microscopie (SCM) of 162 
Université Paris Descartes. This system is equipped with a 63x, 1.4 O.N oil immersion lens 163 
(Plan Neofluor). For oil immersion microscopy, we used oil with refractive index of 1.518 164 
(Zeiss). Image capture was carried out with a definition of 1024x1024 pixels with 8 bit data 165 
for each color. Images were analyzed using Image J software. Total pixel intensity was 166 
quantified using Image J software. 167 
 168 
Chromatin immunoprecipitation  169 
Chromatin immunoprecipitation experiments were carried out as previously described (21). 170 
PCR analysis of inputs or immunoprecipitated DNAs was performed using oligonucleotides 171 
F-40 (5’-GTT TTC CCA GTC ACG AC-3’) and CAT (5’-CCA TTT TAG CTT CCT TAG-172 
3’) to reveal the integrated WT330 and WT110 IFN-β promoter. For the F-40, CAT set of 173 
primers, PCR conditions were as follows: 1 cycle of 94°C for 5 minutes; 20 cycles of 94°C 174 
for 30 seconds, 53°C for 30 seconds and 72°C for 30 seconds; 1 cycle of 72 °C for 10 175 
minutes. A first “cold” PCR was carried out in the presence of 25 pmol of each primer; 1.5 μl 176 
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of the product of the first PCR was subjected to a second “hot” PCR carried out in the 177 
presence of 0.1 μl a-32PdATP (6000 Ci/mmol) and 25 pmol of each primer. 178 
 179 
RT-qPCR 180 
Total RNA was extracted using Tri Reagent (Sigma) according to the manufacturer’s 181 
protocol. 1 μg of total RNA was reversely transcribed using High Capacity cDNA Reverse 182 
Transcription Kit (Applied Biosystems) according to the manufacturers' recommendations 183 
using Random Primers. qPCR was performed using SYBR Green (Thermo Scientific) 184 
reagents: 95°C 15 minutes, then 40 cycles at 95°C 15 seconds, 60°C 1 minute, followed by a 185 
dissociation step. Relative quantification of mRNA expression was calculated using the ∆∆CT 186 
method using three reference genes among Ppib, Hprt1, Utp6c and Rplp0). For fold changes 187 
lower than 1 (translating a repression of the gene’s expression), the inverted values were 188 
determined such that a 0.5 fold change corresponds to -2. Sequences of primers used for RT-189 
qPCR analysis are shown in Table I. 190 
Statistical analysis was carried out using Student T-test or the REST software that uses a Pair-191 
Wise Fixed Reallocation Randomization Test© to determine a P-value. 192 
 193 
RNA interference experiments 194 
L929 cells were transfected using Lipofectamine 2000 (Invitrogen Life Technologies) 195 
with the ON Target Plus SMART Pool of siRNA oligos specific for β-catenin (Thermo 196 
Scientific Dharmacon® L-040628-00) or with a pool of control siRNA sequences (Thermo 197 
Scientific Dharmacon® D-001810-10-05) at a final concentration of 50nM each during 72 h.   198 
 199 
 200 
 201 
 10
Gel retardation assay 202 
Nuclear extracts of murine L929 cells either non-treated or treated with LiCl for 24 h 203 
were incubated with the corresponding 5’ 32P-labeled probes in 20 μl (final volume) of 50 204 
mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA, 10% glycerol and 5 mM dithiothreitol. 205 
When indicated, anti-β-catenin antibody was incubated with the nuclear extracts 1 h at 4°C 206 
prior to the addition of the labeled probe. 207 
 208 
Cytopathic effect assays.  209 
Monolayer cultures of L929 cells in 96-well plates were incubated with LiCl for 24 h 210 
before VSV infection. Before VSV infection, the medium containing LiCl was removed. 211 
Viruses were diluted in medium with serum (2% final concentration) and added directly to the 212 
culture medium. The monolayers were stained with crystal violet as vital dye 24 h after VSV 213 
infection or fixed 8h after VSV infection for immunofluorescence analysis. For measurement 214 
of the cytopathic effet of RVFV, L929 cells either non-treated or treated with LiCl for 24 h 215 
were infected with RVFVZH548 and incubated under an overlay consisting of DMEM, 2% 216 
fetal calf serum, antibiotics and 1% agarose at 37°C. At 3 day p.i., the lytic plaques were 217 
counted after staining with a solution of crystal violet. 218 
 219 
Western blot 220 
 For Western blot, total protein extracts were prepared in RIPA buffer and resolved by 221 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 4-12% precast 222 
gels (Life Technologie). Relative quantification of proteins was carried out using Image 223 
Quant software on scanned WB films. 224 
 225 
Ethics Statement 226 
 11
  Experiments on live mice were conducted according to the French and European 227 
regulations on care and protection of laboratory animals (EC Directive 86/609, French Law 228 
2001-486 issued on June 6, 2001) and the National Institutes of Health Animal Welfare 229 
(Insurance #A5476-01 issued on 02/07/2007). Experimental protocols were approved by the 230 
Animal Ethics Committee #1 of the Comité Régional d’Ethique pour l’Expérimentation 231 
Animale (CREEA), Ile de France (N°2012-0025), and carried out in compliance with Institut 232 
Pasteur Biosafety Committee. 233 
234 
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Results 235 
LiCl treatment enhances constitutive IFN-β gene expression. 236 
 The proximal region of the IFN-β promoter (Fig. 1A), made of negative and positive 237 
regulatory domains, is highly conserved between murine and human cells. The Virus 238 
Responsive Element (VRE) that contains binding sites for transcription factors IRF3, ATF2/c-239 
Jun, NF-κB and YY1 is surrounded by two Negative Regulatory Domains (NRDI and II) 240 
described as regions of nucleosome positioning (18). Sequence analysis of the murine IFN-β 241 
promoter revealed the presence in the NDRII of two potential DNA-binding sequences for 242 
TCF transcription factors. A first site, TCFa, between positions -374 and -367  (5’-243 
TTCAAAGG-3’) that perfectly matches the consensus TCF DNA binding sequence 5’-244 
(A/T)(A/T)CAAAGG-3’ (38). A second site, TCFb, between positions -233 and -226 (5’-245 
CCTTTGcT-3’) that differs from the consensus TCF DNA binding sequence by one base. 246 
Two sequences homologous to the murine TCFb sequence are present in the human IFN-β 247 
promoter, between positions -260 and -253 and +26 and +33 respectively.  248 
The presence of potential TCF binding sites within the proximal region of the IFN-β 249 
promoter suggested that expression of the IFN-β gene could be modulated in response to 250 
pathways inducing nuclear accumulation of β-catenin and formation of TCF/β-catenin 251 
complexes over the IFN-β promoter region. In order to test this hypothesis, we analyzed IFN-252 
β gene expression in non-infected cells, corresponding to an IRF3-NF-κB-ATF2/c-Jun 253 
independent expression that we have considered as constitutive IFN-β expression, before and 254 
after nuclear accumulation of β-catenin. Experiments were carried out in murine fibroblastic 255 
L929 cells, which are potent IFN-β producer cells. In the absence of GSK-3 inhibition, little if 256 
any β-catenin was detected in the nucleus of L929 cells whereas the nuclear distribution of β-257 
catenin was significantly enhanced after treatment of the cells with LiCl, an inhibitor of GSK-258 
 13
3 (Fig. 1B-D). IFN-β gene expression measured by RT-qPCR in LiCl-treated cells compared 259 
to untreated cells, showed that LiCl treatment significantly enhanced the constitutive level of 260 
IFN-β mRNAs (p<10-5) (Fig. 1E) independently of any virus infection. Even though the level 261 
of IFN-β expression measured after LiCl treatment was much lower than that induced during 262 
viral infection (16), it was sufficient to trigger an IFN-β response as reflected by a significant 263 
induction of the expression of two major IFN-stimulated genes (ISGs), Oas1b and Irf7 genes 264 
(Fig. 1F). The effect of LiCl on IFN-β expression was dose dependent. The highest effect, 265 
before reaching saturation, was observed at 20 mM LiCl (Fig. 1G). 266 
Low constitutive levels of IFN-β have been previously shown to synergize with virus 267 
infection for efficient virus-induced IFN-β production (30,48). In order to test if the 268 
enhancement of the constitutive level of IFN-β gene expression induced by LiCl in naïve cells 269 
could affect virus induced IFN-β expression, L929 cells were either pretreated or not with 270 
LiCl before being infected with Newcastle Disease Virus (NDV) that, contrary to LiCl, does 271 
not induce the nuclear accumulation of β-catenin (Fig. 1H and J). As shown in Fig. 1J, 272 
pretreatment of the cells with LiCl significantly potentiated NDV-induced IFN-β expression.  273 
 274 
The effect of LiCl treatment on IFN-β expression is mediated by β-catenin.  275 
In order to confirm that the effect of LiCl treatment on constitutive IFN-β expression 276 
was not due to LiCl treatment per se but required the nuclear accumulation of β-catenin, we 277 
made use of murine hepatocyte AML12 cells that produce IFN-β in response to viral infection 278 
but, by contrast to L929 cells, do not accumulate nuclear β-catenin after LiCl treatment (Fig. 279 
2A and B). Measurement of the expression of IFN-β mRNA in AML12 cells either treated or 280 
not with LiCl, before (Fig. 2C) and after (Fig. 2D) NDV infection, showed that the inability 281 
of LiCl to induce the accumulation of nuclear β-catenin in this particular cell type correlated 282 
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with the inability of LiCl treatment to enhance IFN-β expression either in the absence 283 
(Fig.2C) or presence (Fig. 2D) of virus infection.  284 
The role of β-catenin during LiCl enhancement of IFN-β expression was further 285 
confirmed using siRNAs. For this, L929 cells were mock-transfected or transfected either 286 
with siRNAs directed against β-catenin or with control siRNAs (Fig. 2E-G) before being 287 
treated with LiCl for 24h. Under conditions of diminution of β-catenin mRNA (Fig. 2E) and 288 
protein (Fig. 2F) level, we observed that LiCl treatment had no significant effect on IFN-β 289 
expression compared to cells treated with control siRNAs (Fig. 2G) confirming therefore that 290 
the capacity of LiCl treatment to activate IFN-β expression was mediated by β-catenin.   291 
 292 
LiCl treatment stimulates the recruitment of β-catenin on the IFN-β promoter through 293 
the NRDII promoter region containing a TCF binding site. 294 
 IRF3 transcription factor is known to promote IFN-β expression, yet its activation, 295 
nuclear translocation and subsequent IFN-β promoter binding, require the previous activation 296 
of PRRs. The capacity of LiCl treatment to affect IFN-β gene expression in the absence of 297 
infection showed that activation of the transcriptional capacity of the IFN-β promoter could 298 
occur independently of IRF3, through a mechanism that we hypothesized to be TCF/β-299 
catenin-dependent. In order to test this hypothesis, we made use of previously established 300 
L929 cell lines carrying integrated into their genome the proximal IFN-β promoter region 301 
fused to the CAT reporter gene either from positions -330 to +20 (L929 WT330 cells) or from 302 
positions -110 to +20 (L929 WT110 cells) (45). The NRDI region and the entire VRE region, 303 
containing the IRF3 binding site, are present in both promoters whereas the NRDII region, 304 
containing a TCF binding site, is only present on the WT330 promoter (Fig. 3A). Therefore, 305 
contrary to the WT330 promoter that contains a TCF binding site, no TCF binding site is 306 
present in promoter WT110.  307 
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ChIP analysis presented in Fig. 3B indicates that LiCl treatment induced β-catenin 308 
binding to the WT330 promoter but not to the WT110 promoter, demonstrating that β-catenin 309 
binding to the IFN-β promoter that occurred in the absence of virus infection required the 310 
NRDII region containing a TCF binding site.  311 
If, as hypothesized, the activation of IFN-β expression induced after LiCl treatment 312 
required the recruitment of β-catenin on the IFN-β promoter, then only the WT330 promoter 313 
was expected to respond to LiCl treatment. In order to test this prediction, we pretreated L929 314 
WT330 and WT110 cells with LiCl and assayed the corresponding CAT activities (Fig. 3C). 315 
As expected, LiCl treatment enhanced by 4-folds the constitutive transcriptional capacity of 316 
the WT330 promoter, but not that of the WT110 promoter. Thus reinforcing the indispensable 317 
role of the promoter region positioned 5’ of the VRE, containing a TCF binding site, for LiCl 318 
treatment to enhance the constitutive transcriptional capacity of the IFN-β promoter.  319 
The role of the NRDII region containing a TCF binding site during LiCl-dependent 320 
promoter activation was also analyzed after virus infection. As shown in Fig. 3D, LiCl 321 
treatment enhanced the virus-induced activity of the WT330 promoter, but not that of the 322 
WT110 promoter. Therefore, the presence of the NRDII region containing a TCF-binding site 323 
was also required for the LiCl-dependent enhancement of the virus-induced transcriptional 324 
capacity of the IFN-β promoter. The presence of only the VRE region, containing the IRF3 325 
binding site (promoter WT110), was not sufficient to either recruit β-catenin or mediate LiCl 326 
enhancement of the constitutive as well as virus-induced transcriptional capacity of the IFN-β 327 
promoter. 328 
LiCl that is considered as an inhibitor of GSK-3 can also affect the activity of other 329 
kinases. In order to further investigate if the effect of LiCl on IFN-β expression was the 330 
consequence of the inhibition of GSK-3, L929wt330 and wt110 cells were treated with two 331 
other inhibitors of GSK-3, SB216763 and inhibitor IX. Similarly to LiCl, a dose dependent 332 
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activation of the transcriptional capacity of the WT330 promoter was observed in the 333 
presence of increasing amounts of SB216763 (Fig. 3E). Also, treatment with either SB216763 334 
or inhibitor IX had the same effect than LiCl, activating the transcriptional capacity of 335 
WT330 promoter but not that of WT110 promoter (Fig. 2E and F). Since GSK-3 is a common 336 
target for these three inhibitors, the fact that LiCl, SB216763, and inhibitor IX had the same 337 
effect on the transcriptional capacity of the IFN-β promoter strongly supports the hypothesis 338 
that LiCl dependent enhancement of IFN-β expression is the consequence of the inhibition of 339 
GSK-3.      340 
 341 
The effect of LiCl treatment on IFN-β expression is mediated by TCF. 342 
 Gel retardation assays were used to analyze the capacity of TCF binding sites present 343 
within the NRDII region of IFN-β promoter to form complexes displaying the characteristics 344 
of TCF-DNA complexes. For this, we used oligonucleotides containing the sequence of wild-345 
type, mutated TCFa or mutated TCF b sites. TCF binding sites were mutated in their core 346 
motif containing the stretches of A required for the HMG box of TCF factors to interact with 347 
DNA. The TCFa site was mutated to give rise to TCFmutA (5’-TTCggAGG-3’) site and the 348 
TCFb site was mutated to give rise to TCFmutB (5’-CCccTGcT-3’) site. The corresponding 349 
radioactively labeled, double-stranded DNA probes were incubated with nuclear extracts 350 
prepared from L929 cells either non-treated or treated by LiCl during 24h. Whereas complex 351 
formation was only weakly observed in the presence of nuclear extracts from non-treated 352 
cells, a protein-DNA complex (indicated by an arrow in Fig. 4A) was clearly formed when 353 
the DNA probes containing the wild-type TCFa or TCFb sites were incubated with nuclear 354 
extracts from LiCl treated cells. As expected for a TCF-DNA complex, complex formation 355 
was disrupted when the core region of the TCF DNA binding sequence was mutated as in 356 
TCFmutA and mutB probes (Fig. 4B). T-Cell Factors interact with the minor groove of A/T 357 
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base pairs through their HMG-box and therefore are known to display affinity for I/C 358 
sequences that resemble A/T sequences in the minor groove (49, 50). Therefore, as expected 359 
for a TCF-DNA complex, the previous incubation of nuclear extracts with non-labeled 360 
polydI/dC sequences inhibited complex formation with the radioactively labeled TCFA probe 361 
(Fig. 4B). Finally, incubation of the nuclear extracts with anti-β-catenin antibodies affected 362 
the formation of the protein-DNA complex that in the presence of antibodies was less intense 363 
and supershifted (Fig. 4B), indicative of the presence of β-catenin within the complex. 364 
To confirm the role of TCF binding sites in the LiCl dependent activation of the IFN-β 365 
promoter transcriptional capacity, the IFN-β promoter region from positions -458 to +36 366 
either wild-type or mutated in one or both TCF binding sites was cloned in front of the 367 
luciferase reporter gene. After transfecting the corresponding plasmids into L929 cells, the 368 
transfected cells were either treated or not with LiCl before being infected with NDV. The 369 
corresponding luciferase activities were measured (Fig. 4C). Contrary to wild-type and mutB 370 
promoters whose corresponding transcriptional capacities could be activated following LiCl 371 
treatment, promoter mutA partially lost its capacity to be activated by LiCl and no activation 372 
was observed in the case of the promoter mutAB. Therefore, results obtained here with TCF 373 
mutated promoters demonstrated that the presence of at least one TCF binding site was 374 
required for LiCl to activate the transcriptional capacity of the IFN-β promoter. In the context 375 
of the promoter region cloned in these constructions (from -458 to +36), the TCFa that 376 
perfectly matches the consensus sequence site appeared more efficient than the TCFb site. 377 
In order to definitively confirm the role of TCF/β-catenin complexes during LiCl 378 
enhancement of the transcriptional capacity of the endogenous IFN-β promoter, we used 379 
iCRT3, which is a potent inhibitor of TCF4/β-catenin complexes (51). The presence of IFN-β 380 
mRNAs was measured in NDV-infected L929 cells that were either non-treated or pretreated 381 
with LiCl during 24 or 48 h in the absence or presence of different amounts of iCRT3 382 
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corresponding to the range of iCRT3 concentration necessary to inhibit TCF/β-catenin 383 
dependent transcription of the Axin-2 and CycD1 (51). A dose-dependent inhibition of the 384 
effect of LiCl on IFN-β expression was observed in the presence of iCRT3, and this in the 385 
case of 24h as well as 48h (Fig. 4D) of LiCl treatment. In the same samples, iCRT3 also 386 
inhibited the activation of the expression of the gene coding for CyclinD1 (Fig. 4E), which is 387 
known to be regulated by TCF/β-catenin complexes. Overall demonstrating that the capacity 388 
of LiCl to enhance IFN-β expression was mediated by TCF/β-catenin complexes. 389 
  390 
LiCl treatment confers an efficient antiviral response. 391 
 Fig. 1E shows that LiCl-dependent enhancement of the constitutive level of IFN-β 392 
expression was sufficient to lead to a significant activation of the expression of two major 393 
ISGs, Oas1b and Irf7, responsible for the RNaseL-dependent degradation of viral ARN and 394 
for the amplification of the IFN-β response respectively. In order to analyze the efficiency of 395 
such LiCl-induced interferon response with respect to the establishment of an antiviral state, 396 
we compared the cytopathic effect (CPE) of Vesicular Stomatitis Virus (VSV) in murine 397 
L929 cells either pretreated or not with LiCl. Indeed, following infection of murine L929 cells 398 
with VSV, cell viability is expected to decrease as the amount of VSV increases unless an 399 
efficient IFN-β response had been mounted previously to VSV infection (52). 400 
L929 cells pretreated or not with LiCl were infected with increasing titers of VSV. 401 
Twenty-four hours after infection, the cells were stained with crystal violet, which detects 402 
CPE as a decrease in staining intensity. As shown in Fig. 5A, at low multiplicity of infection 403 
(MOI), cells pretreated with LiCl displayed less VSV-induced CPE than untreated cells, 404 
highlighting the capacity of LiCl treatment to induce an efficient antiviral response protecting 405 
cells against VSV-induced cell death. The capacity of LiCl treatment to confer an efficient 406 
antiviral response at low MOI is further depicted in photographs of culture fields of LiCl-407 
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treated versus untreated cells 24h after post infection (p.i.). Whereas the majority of non-408 
treated cells died 24h p.i., LiCl-treated cells grew to confluence displaying resistance to 409 
infection (Fig. 5B).  410 
 Even though at higher MOI all cells died by 24 h p.i. regardless of LiCl treatment (Fig. 411 
5A), at a MOI of 1 the percentage of cells detected as infected by fluorescent staining was 412 
significantly lower at earlier times after infection (8h p.i.) among LiCl-treated cells than 413 
among untreated cells (Fig. 5C and D). This is indicative of the capacity of LiCl-treated cells 414 
to dampen the kinetics of virus multiplication.   415 
 416 
The canonical Wnt/β-catenin pathway is a major target of Rift Valley fever virus. 417 
 Cellular pathways participating in the establishment of an effective antiviral response 418 
are expected to be affected during viral infections: either “positively”, leading to the 419 
activation of the host antiviral response, or “negatively”, in the case of viruses capable to 420 
efficiently inhibit the cellular antiviral response. Therefore, if as suggested in this work, a 421 
TCF/β-catenin transcription complex participates in the establishment of an efficient antiviral 422 
response then pathways regulating active TCF/β-catenin complex formation are expected to 423 
be targeted during viral infection.  424 
The effect of a viral infection upon the canonical Wnt/β-catenin pathway, which is a 425 
major regulator of the formation of active TCF/β-catenin complexes, was analyzed here 426 
during infection with Rift Valley fever virus (RVFV) for which two different strains, 427 
pathogenic and non-pathogenic are available. The wild type RVFV ZH548 strain (ZH) of the 428 
virus that codes for a non-structural NSs protein, suppresses IFN-β expression and is highly 429 
pathogenic causing severe illness in humans and animals (53-55), whereas the RVFV 430 
ZH548∆NSs strain (∆NSs), deleted for the region coding for NSs protein, strongly activates 431 
IFN-β expression and is fully avirulent (56).  432 
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The viral NSs protein, which is a major factor responsible of RVFV pathogenicity, has 433 
the characteristic to form filamentous structures in nuclei of infected cells abnormally 434 
trapping within these structures transcription factors and co-factors of the host (21,57). 435 
During a recent genome wide search for regulatory DNA regions of the host interacting with 436 
RVFV NSs protein, several genes associated with the canonical Wnt/β-catenin pathway were 437 
identified as interacting with NSs (Table II) (58). Among these were genes coding for several 438 
WNT ligands (Wnt1, Wnt2, Wnt6 and Wnt8b), for antagonists of Wnt signaling (Apcdd1, 439 
Dkk1 and Kremen2), for members of the multiprotein complex regulating the degradation of 440 
β-catenin (Gsk3b, Gsk3a and Axin2), for β-catenin itself (Ctnnb1) as well as for members of 441 
the TCF/β-catenin complex (Tcf7l2, Lef1 and Bcl9). Also, DNA regulatory sequences 442 
associated with genes coding for casein kinases (Csnk1d, Csnk1g2, Csnk1g3 and Csnk2a2) 443 
known to positively regulate the canonical Wnt/β-catenin signaling pathway at different 444 
levels were present among cellular DNA regions targeted by NSs. 445 
Using RT-qPCR, we analyzed the effect of RVFV infection, either pathogenic (ZH 446 
strain) or non-pathogenic (∆NSs strain), upon the expression of the genes related to canonical 447 
Wnt/β-catenin pathway identified as significantly interacting with NSs. For this, RNA was 448 
purified from three different cell types targeted by RVFV (L929 fibroblasts, AML12 449 
hepatocytes and bone marrow derived macrophages (BMDM)) either non-, ∆NSs- or ZH-450 
infected. After reverse transcription, the fold change in the expression level of genes of 451 
interest (including the gene coding for IFN-β) was calculated with respect to non-infected 452 
cells using three different reference genes (Fig. 6).  453 
As expected, infection with the avirulent ∆NSs strain strongly activated IFN-β gene 454 
expression in the three cell types tested, whereas infection with the virulent ZH strain 455 
maintained the IFN-β expression in an abnormally repressed state.  456 
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Both strains affected the Wnt/β-catenin pathway but with opposite effects. Infection 457 
with the non-pathogenic ∆NSs strain led to i) the activation of the expression of genes coding 458 
for casein kinases, with Csnk1d and Csnk2a2 genes activated in the three cell types tested, 459 
and Csnk1g3 activated in fibroblasts and BMDM; ii) the activation of the expression of genes 460 
coding for factors essentials for the formation of an active β-catenin transcription complex 461 
such as Bcl9 and Tcf7l2 in hepatocytes and BMDM; and iii) the repression of the expression 462 
of the Axin2 gene, a negative regulator of the canonical Wnt/β-catenin pathway (59), in 463 
hepatocytes. On the contrary, infection with ZH led in BMDM to the inhibition of the 464 
expression of Csnk1d and Csnk2a2 genes, and the activation of the expression of Axin2 gene. 465 
Also, a slight inhibition of the expression of Bcl9 gene was observed in fibroblasts and 466 
hepatocytes. 467 
 As shown in Fig. 7, all the effects observed after non-pathogenic ∆NSs infection 468 
tended towards the formation of an active nuclear β-catenin complex. On the contrary, the 469 
effects observed after infection with the pathogenic ZH strain of the virus tended against the 470 
formation of a nuclear β-catenin transcription complex.  471 
Virus-induced IFN-β expression depends on the presence of several transcription 472 
factors and co-factors that synergize to give rise to a maximum of expression (16-27). 473 
Therefore, even though TCF/β-catenin complexes could participate on the induction of IFN-β 474 
expression, they should not be considered as alone responsible of the strong IFNβ expression 475 
induced during infection by ∆NSs. Similarly, even though RVFV targeting of TCF/β-catenin 476 
complex formation could be participating in the RVFV-induced inhibition of IFN-β 477 
expression, this should not be considered as alone responsible of the complete lack of IFN-β 478 
expression in RVFV infected cells that we have previously shown to be related to the capacity 479 
of NSs to maintain the IFN-β promoter region associated to a transcriptionally repressive 480 
environment (16, 21). 481 
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Nevertheless, the fact that avirulent and virulent strains of RVFV had opposite, mirror, 482 
effects upon the Wnt/β-catenin pathway suggested that this pathway could be playing a role in 483 
mounting an efficient innate antiviral response against RVFV infection. 484 
 485 
A potential role for β-catenin protein in setting up an antiviral response against RVFV 486 
infection. 487 
In order to test the effect of RVFV infection upon the level of β-catenin in vivo, the 488 
presence of β-catenin was analyzed in the liver and brain of mice that were either non-489 
infected, or infected with ∆NSs or ZH strains. Of note, the liver and brain are two main 490 
organs targeted during RVFV infection (60). Mice were euthanized at days 3 and 5 p.i. and 491 
the liver and brain were removed; one half of each organ was used for total protein 492 
purification and Western blot analysis and the other half for RNA purification and RT-qPCR 493 
analysis. Whereas no variation was observed for β-catenin at the transcriptional level (data 494 
not shown), Western blot analysis showed significant variations at the protein level in the 495 
liver of ZH-infected mice at day 5 p.i. (Fig. 8A). Under these conditions, the average relative 496 
level of β-catenin significantly diminished in the liver of all ZH-infected mice compared to 497 
non-infected and ∆NSs-infected mice where on the contrary, the level of β-catenin was 498 
increased in ∆NSs-infected mice (Fig. 8A).  499 
Viral targeting of β-catenin was further analyzed with respect to the presence of the 500 
virus (as translated by the presence of viral mRNAs coding for viral proteins N and NSs) in 501 
the liver and the brain of each mouse under each condition. In the case of ZH-infected mice, 502 
viral N and NSs mRNAs were clearly detected at day 5 p.i. in the liver of mouse #1, 2 and 3 503 
and by day 3 p.i. in the liver of mouse #1 (Fig. 8B) but remained essentially undetectable in 504 
the brain of infected mice. Therefore, the effect of RVFV infection upon the level of β-505 
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catenin appeared correlated with the presence of the virus suggesting that β-catenin could be 506 
playing a role protecting against ZH replication. 507 
If as hypothesized β-catenin played a role in the antiviral response against RVFV 508 
infection, then LiCl treatment should have a protective effect. In order to test this, L929 cells 509 
were either non-treated or pretreated with LiCl during 24 h before infection with the virulent 510 
ZH strain of RVFV. In agreement with a potential physiological role for β-catenin inhibiting 511 
RVFV replication, pretreatment with LiCl significantly diminished the number of lytic 512 
plaques induced by RVFV (Fig. 8C).  513 
514 
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Discussion 515 
In this work we have demonstrated that cell treatment with LiCl, an inhibitor of GSK-516 
3, leads to the enhancement of the constitutive (namely IRF3-NFκB-ATF2/cJUN-517 
independent) as well as virus-induced level of IFN-β gene expression, provided that LiCl 518 
treatment be correlated with the IFN-β promoter recruitment of β-catenin. The effect of LiCl 519 
on the constitutive as well as virus-induced transcriptional capacity of the IFN-β promoter 520 
required the presence of the IFN-β promoter region containing TCF-binding sites, positioned 521 
5’ of the VRE region. Results obtained in this work with siRNA directed against β-catenin 522 
added to results obtained with iCRT3, an inhibitor of TCF/β-catenin complexes (51) as well 523 
as results obtained with IFN-β promoters carrying mutated TCF sites, demonstrated that the 524 
capacity of LiCl to enhance IFN-β expression was mediated through TCF/β-catenin 525 
complexes rather than IRF3 as suggested until now in the literature.  526 
In the absence of β-catenin, TCFs act as transcriptional repressors recruiting co-527 
repressor complexes. The TCF sites we describe here on the IFNβ promoter are positioned 528 
over the NRDII region that corresponds to a negative regulatory region. It is therefore 529 
possible that in the absence of β-catenin, TCF factors could be participating in the 530 
establishment of the repressive state of the IFN-β promoter alongside with other repressors 531 
and co-repressors previously described as participating in the establishment of the repressive 532 
state of the IFNβ promoter such as the SAP30/Sin3A/NCoR/HDAC3 complex (21).  533 
Such capacity of LiCl to enhance the transcriptional activity of the IFN-β promoter, 534 
we also observed it after treatment of the cells with SB216763 and inhibitor IX, which are 535 
two other inhibitors of GSK-3, suggesting that the capacity of LiCl to enhance IFN-β 536 
expression observed in this work could be the consequence of the inhibition of GSK-3 that is 537 
a target that these three inhibitors have in common. In agreement with our results, activation 538 
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of IFN-β expression after GSK-3 inhibition by SB216763 has been previously described by 539 
several groups in the context of the IFN-β expression induced in response to LPS or polyI:C  540 
(39, 61, 62), and a positive effect for β-catenin on IFN-β expression has been reported under 541 
different contexts (41, 43, 63).  542 
However, inhibition of GSK-3 has also been associated to a negative effect on virus-543 
induced IFN-β expression (44). This was observed in the context of SeV infection and 544 
required the SeV-induced secretion of WNT2B and WNT9 ligands that in association with the 545 
nuclear accumulation of β-catenin triggered a negative feedback loop to reduce and control an 546 
excessive IFN-β response. The SeV-dependent negative effect of GSK-3 inhibition on IFN-β 547 
expression was shown to be independent of TCF/β-catenin driven transcription and therefore 548 
different from the positive effect of GSK-3 inhibition we have observed here on IFN-β 549 
expression. Even though the exact mechanism leading to IFN-β inhibition in the case of SeV 550 
infection has remained undetermined, it was suggested to depend on the association of IRF3 551 
with β-catenin, affecting the late stage of IRF3 transcriptional activity (44). In our study, the 552 
TCF/β-catenin activation of IFN-β expression observed in the presence of LiCl, was observed 553 
not only in non-infected cells but also after NDV infection including during the period of the 554 
establishment of the post-transcriptional turn-off of the IFN-β gene (Fig. 1 I, 6 and 8 hr p.i.). 555 
Differences between our results and those of Baril et al. could be related to the fact that 556 
contrary to SeV, NDV infection does not induce WNT signaling as translated by the inability 557 
of NDV to induce accumulation of nuclear β-catenin even at late times after infection.  558 
WNT ligands lead to the nuclear accumulation of β-catenin through a mechanism 559 
different from that of LiCl. While LiCl inhibits the kinase activity of GSK-3 preventing β-560 
catenin degradation, WNT ligands induce the plasma membrane recruitment of GSK-3 and 561 
AXIN1, disrupting the cytoplasmic GSK3/AXIN/APC destruction complex of β-catenin. 562 
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Thus, WNT ligands lead to the accumulation of nuclear β-catenin without affecting the kinase 563 
activity of GSK3. Lei et al. (64) have described a positive effect of GSK-3 upon IFN-β 564 
expression and response independent of the kinase activity of GSK-3, that required the direct 565 
interaction of GSK-3 with TBK1 necessary for the TBK1-dependent activation of IRF3 (64). 566 
It is possible that the plasma membrane recruitment of GSK-3 induced by WNT ligands in the 567 
context of SeV infection, could interfere with the capacity of GSK-3 to interact with and 568 
activate TBK1, therefore diminishing through a feedback loop the pool of phosphorylated 569 
active IRF3.  570 
Our results showed that the LiCl-dependent activation of the IFN-β expression was 571 
correlated with the induction of an effective antiviral response. This in agreement with 572 
recently published data describing the capacity of LiCl to inhibit H7N7 influenza A (43) and 573 
Porcine Reproductive and Respiratory Syndrome (PRRS) (65) virus replication. Interestingly, 574 
both these works show results indicative of a role for TCF/β-catenin complexes on these 575 
LiCl-dependent inhibitions of viral infection. Contrary to these and our results, Wang et al. 576 
(62) have described a LiCl-dependent attenuation of IFN-β expression and viral infection, 577 
through a mechanism independent of LiCl/β-catenin complexes related with the capacity of 578 
LiCl to inhibition TBK1. To our knowledge, this is the only work that has described an 579 
inhibitory effect of LiCl on TBK1. This is an effect of LiCl that we did not observe under our 580 
experimental conditions. Notwithstanding that NDV-induced IFN-β expression relies on the 581 
activation of RIG-I and TBK1, we never observed an inhibitory effect of LiCl treatment on 582 
the IFN-β expression induced by NDV. Not even under conditions when the positive effect of 583 
LiCl was not detected, such as when LiCl was unable to induce accumulation of nuclear β-584 
catenin in AML12 cells (Fig. 2 A-D) or unable to induce β-catenin recruitment as in the case 585 
of the WT110 IFN-β promoter (Fig. 3). Differences between our results, as well as results 586 
obtained in the context of influenza (43) and PPRS (65) virus, and the work of Wang et al. 587 
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(62) could result from variations on the state of TBK1 under our respective cellular models. 588 
TBK1 is an enzyme whose activity strongly relies on its cellular localization that can be 589 
affected by a wide diversity of mechanisms and signaling pathways including not only 590 
pathogens but also cell growth and proliferation (66).  591 
Further emphasizing the potential role for TCF/β-catenin complexes in the 592 
establishment of an efficient innate antiviral response, we show here that LiCl treatment of 593 
L929 cells protected these cells against the cytopathic effect of RVFV that we show here to 594 
negatively target β-catenin in the liver of infected mice. Viral targeting of the formation of 595 
active nuclear β-catenin transcription complexes has been observed in the context of 596 
infections with other viruses such as influenza H1N1 virus, Human Cytomegalovirus 597 
(HCMV), Venezuelan Equine Encephalitis Virus (VEEV) and HIV-1 (40,67-69). Such 598 
tendency of viruses to negatively target β-catenin, is in a agreement with the scenario of a 599 
positive role for β-catenin during the establishment of an efficient antiviral response. 600 
Several reports in the literature point at physiological roles for constitutive IFN-β 601 
expression in the absence of viral infection (33). However, little is known concerning the 602 
mechanism(s) capable to directly modulate IFN-β expression in naïve cells except for results 603 
obtained with c-Jun-/- murine embryonic fibroblasts that identified transcription factor c-Jun 604 
as a potential regulator of the constitutive level of IFN-β expression (70). Since inhibition of 605 
GSK-3, leading to the formation of nuclear TCF/β-catenin complexes, can be reached not 606 
only physiologically through pathways associated with Wnt ligands and Akt phosphorylation 607 
but also pharmaceutically, results shown here open the possibility of a wide range of cellular 608 
and extra-cellular mechanisms susceptible to modulate the level of IFN-β expression in the 609 
absence of infection. 610 
If we consider that TCF/β-catenin complexes can directly affect constitutive levels of 611 
IFN-β expression in the absence of pathogens as described here, then the existence of cross-612 
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talks between β-catenin and IFN-β should also be considered beyond the issue of pathogen 613 
infection. For example, the capacity of β-catenin to modulate inflammatory and immune 614 
responses (71) could be related to its ability to modulate the expression of IFN-β, which is a 615 
major regulator of immunity and inflammatory responses. Also, a cross-talk between β-616 
catenin and IFN-β during the establishment and/or treatment of neurological disorders such as 617 
Alzheimer disease and multiple sclerosis should be considered since both Wnt/β-catenin 618 
pathway and IFN-β response have been associated to these neurological pathologies (72-74).  619 
Although modulation of the constitutive level of IFN-β expression has probably been 620 
observed in the past by many researchers, it has often been neglected because it seemed only 621 
minor compared to pathogen-induced IFN-β expression. Nevertheless, even though weak, the 622 
biological significance of constitutive IFN-β expression is no longer to be demonstrated (33). 623 
Therefore, mechanisms capable to modulate constitutive IFN-β expression, such as the one 624 
our results demonstrate here, should gain interest in the future. 625 
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Figure legends 858 
Figure 1. LiCl treatment enhances the constitutive and virus-induced IFN-β expression. 859 
(A) Schematic representation of the general organization of the murine IFN-β promoter 860 
showing the Negative Regulatory Domain (NRD) I and II as well as the Virus Responsive 861 
Element (VRE). (B and H) Immunolocalisation of β-catenin in L929. Cells were either non-862 
treated (NT), treated with 20mM LiCl (LiCl) during 24h, or infected with NDV, labeled with 863 
an anti-β-catenin antibody (a, d, g, h) and a DNA intercalating agent to visualize the nucleus 864 
(ToPro3; b, e, h, k). Nuclei were outlined as shown in merge images and total green pixel 865 
intensity corresponding to β-catenin labeling in the nucleus was quantified (C). β-catenin was 866 
analyzed by Western blot (D) in nuclear extracts from L929 cells either non treated (NT) or 867 
treated with 20 mM LiCl (LiCl) during 24h. IFN-β mRNA (E and I) and Oas1b or IRF7 868 
mRNA (F) were analyzed by RT-qPCR: in non-infected L929 cells either non-treated (NT) or 869 
LiCl treated (LiCl) (E-G); at different times post-infection (p.i) in L929 cells mock- or NDV-870 
infected, either non-treated (NT) or pre-treated with LiCl (LiCl) (I). In (E-G), the 871 
corresponding fold inductions were calculated with respect to non treated cells; and in (I), the 872 
corresponding fold inductions were calculated with respect to non-infected and non-treated 873 
cells. C) n=33 (minimum) to 71 (maximum) counted nuclei; E) n=42 from 13 independent 874 
experiences; F) n=18 from 6 independent experiences; I) n=6. Student test: p-value less than 875 
0.001 (***), 0.01 (**) and 0.05 (*). All images correspond to one confocal section.  Scale bar 876 
= 10µM. 877 
 878 
Figure 2. LiCl enhancement of IFN-β expression is mediated by β-catenin. (A-D) AML12 879 
cells were either non-treated (NT) or treated with 20mM LiCl (LiCl) during 24h and either 880 
non-infected (A-C) or NDV-infected (D). (A and B) Cells were labeled with an anti-β-catenin 881 
antibody (a, d) and a DNA intercalating agent to visualize the nucleus (ToPro3; b, e). Nuclei 882 
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were outlined as shown in merge images (c, f), and total green pixel intensity corresponding 883 
to β-catenin labeling in the nucleus was quantified (B). IFN-β mRNA (C and D) was 884 
analyzed by RT-qPCR in non-infected (C) and NDV-infected (6h p.i.) (D) cells either non-885 
treated (NT) or pre-treated with LiCl (LiCl). The corresponding fold inductions were 886 
calculated with respect to non-treated (C) or non-infected and non-treated (D) cells. (E-G) 887 
L929 cells were either mock-transfected (mock) or transfected with β-catenin specific (siβcat) 888 
or control (siCtrl) siRNA for 72h. β-catenin mRNA (E) and protein level (F) were analyzed 889 
by RT-qPCR and WB respectively. (G) Post-siRNA, cells were either non-treated (NT) or 890 
treated with 20mM LiCl (LiCl) during 24h before being NDV-infected. IFN-β mRNA was 891 
analyzed by RT-qPCR. (E and G) the corresponding fold inductions were calculated with 892 
respect to mock-transfected, non-treated and NDV-infected cells (n=3). Student test: p-value 893 
less than 0.001 (***) and 0.01 (**). All images correspond to one confocal section.  Scale bar 894 
= 10µM. 895 
Figure 3. Interaction of β-catenin with the IFN-β promoter region containing a TCF 896 
binding site is necessary for LiCl enhancement of IFN-β promoter activity. (A) 897 
Schematic representation of the WT330 and WT110 murine IFN-β promoters fused to the 898 
CAT reporter gene and integrated into the genome of L929 WT330 and L929 WT110 cell 899 
lines respectively. (B to D) β-catenin binding to WT330 and WT110 promoters and 900 
corresponding CAT activities were analysed in L929 WT330 and WT110 cells either non-901 
treated (NT) or treated with LiCl 20mM (LiCl). (B) Genomic DNA was collected 24h post-902 
LiCl treatment and immunoprecipited with anti β-catenin (α-β-cat) or anti NSs (α-NSs, 903 
negative control) antibodies. Increasing amounts (μL) of immunuprecipitated DNA (IP), as 904 
well as non immunoprecipitated genomic DNA (Input) were amplified by semi-quantitative 905 
PCR using specific primers for the WT330 and WT110 integrated promoters. (C) Cells were 906 
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collected post-LiCl treatment and their CAT activities quantified. The corresponding fold 907 
inductions were calculated with respect to non-treated cells (n=12 for WT330 and n=6 for 908 
WT110 cell lines). (D) Post-LiCl treatment, cells were further mock- or NDV-infected, 909 
collected at different times post-infection and the corresponding CAT activities were 910 
quantified. The corresponding fold inductions were calculated with respect to non-infected 911 
non-treated cells (n=4). (E and F) CAT activities of L929 cells either non-treated (NT) or 912 
treated with 50 μM of SB216763 (E) or 30μΜ of IX inhibitor during 24h (F). Cells were 913 
further mock- or NDV-infected, collected 8h post-infection and the corresponding CAT 914 
activities quantified. The corresponding fold inductions were calculated with respect to non-915 
infected non-treated cells. 916 
 917 
Figure 4. TCF binding sites mediate LiCl-dependent activation of the IFN-β promoter. 918 
(A and B) Equal amounts of nuclear extracts (N.E) prepared from L929 either non-treated (-919 
LiCl) or treated with 20mM LiCl (+LiCl) during 24h were incubated with the radioactively 920 
labeled probes corresponding to wild type TCFa (TCFA) and TCFb (TCFB) or mutated TCFa 921 
(TCFmutA) and TCFb (TCFmutB) sites. When indicated, nuclear extracts were incubated 922 
with 500 ng of poly dI/dC or anti-β-catenin antibodies before adding the probes. (C) L929 923 
cells transfected with plasmids containing luciferase reporter gene under the control of the 924 
IFN-β promoter either WT or mutated at the TCFa site (mutA), the TCFb site (mutB) or the 925 
TCFa and b sites (mutAB) were either non-treated (NT) or pre-treated with LiCl (LiCl) before 926 
infection with NDV. Cells were collected 7h p.i. and the luminescence was quantified with 927 
n=3. (D and E) L929 cells were either non-treated (NT) or treated with 20mM LiCl (LiCl) 928 
during 24h or 48h in the presence or absence of iCRT3 before being NDV-infected. IFN-β 929 
(D) or cyclin D1 (E) mRNA was analyzed by RT-qPCR and the corresponding fold 930 
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inductions were calculated with respect to non-treated NDV-infected (D) or non-infected (E) 931 
cells; D) n=3. Student test: p-value less than 0.01 (**) and 0.05 (*).  932 
Figure 5. LiCl treatment confers an antiviral state. Monolayers of L929 cells either non-933 
treated (NT) or pre-treated with LiCl 20mM for 24h were infected with VSV. (A) Cytopathic 934 
effect induced by increasing MOI of VSV was assayed by crystal violet dye staining 24h after 935 
infection; (B) Photographs of typical culture fields. (C and D) Cells were fixed 8h after 936 
infection (MOI=1), labeled with an antibody directed against the N protein of VSV (displayed 937 
in gray) and ToPro3 (blue); merge images of the corresponding culture fields are displayed in 938 
(C). The % of infected cells, as determined by the presence of N protein encoded by VSV 939 
(fluorescence displayed in gray) was determined from a total of 7876 untreated and 9024 940 
LiCl-treated cells counted with n=4 (D). 941 
 942 
Figure 6. Infection with RVFV affects the Wnt/β-catenin pathway at the transcriptional 943 
level. The expression of genes associated to the Wnt/β-catenin pathway previously identified 944 
as interacting with the NSs protein of RVFV (listed in Table II) was measured in three 945 
different cell types corresponding to fibroblast (L929), hepatocytes (AML12) and Bone 946 
Marrow Derived Macrophages (BMDM) either mock-, RVFZH548- (ZH) or RVFV∆NSs- 947 
(∆NSs) infected. RNAs purified from mock- or virus-infected cells (8h p.i.) were analyzed by 948 
RT-qPCR with primers specific for each gene of interest. The change in gene expression was 949 
calculated in ZH and ∆NSs-infected cells with respect to mock-infected cells. The horizontal 950 
broken lines indicate the cutoff value for upregulation (+1.5 fold) and downregulation (-1.5 951 
fold). The effect of virus infection upon the expression of genes coding for WNT ligands as 952 
well as for antagonist of Wnt signaling (Apcdd1, Dkk1 and Kremen2) could not be tested 953 
since the corresponding mRNA remained undetectable in the three cell types analyzed here. 954 
n≥3 for each cell line. 955 
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 956 
Figure 7. Non-pathogenic and pathogenic strains of RVFV have opposite effects on the 957 
Wnt/β-catenin pathway. Genes participating in the Wnt/β-catenin pathway whose promoter 958 
regions were identified as significantly interacting with RVFV NSs protein during ChIP-on-959 
chip experiments, listed in Table II, are shown in gray. Genes whose expressions were 960 
affected after infection with either the non-pathogenic ∆NSs or the pathogenic ZH strain of 961 
RVFV with respect to mock-infected cells are indicated by blue (upregulated) or red 962 
(downregulated) arrows. 963 
 964 
Figure 8. A physiological relevance for β-catenin protein level during RVFV infection. 965 
(A and B) β-catenin protein and viral N and NSs RNA levels were evaluated in liver and 966 
brain of mice either non-infected (NI) or at days 3 and 5 p.i. with RVFVZH548 (ZH) or 967 
RVFV∆NSs (∆NSs). (A) β-catenin protein level was analysed by Western blot and estimated 968 
densitometrically by comparison with the band intensity of GAPDH; values were averaged 969 
from (n) independent samples per time point with n=3 mice (NI), n=6 mice (ZH 3 days and 970 
∆NSs 3 and 5 days) and n=4 mice (ZH 5 days). Fold induction was calculated by comparison 971 
of the relative β-catenin level in infected versus non-infected (NI) samples. (B) The relative 972 
level of viral N and NSs mRNA were estimated by comparison with the expression of three 973 
reference genes (Ppib, Hprt1 and Utp6c). (C) Number of lytic plaques formed in monolayers 974 
of L929 cells either non treated or pre-treated with LiCl 20 mM during 24h and infected with 975 
RVFVZH548. Cells were fixed and stained with crystal violet 3 days p.i. (n=4). Student test: 976 
p-value less than 0.001 (***), 0.01 (**) and 0.05 (*). All images correspond to one confocal 977 
section.   978 
979 
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Table I. Sequences of the different primers used during qPCR assays. 980 
 Forward Reverse 
Ppib GGAGATGGCACAGGAGGAAA CCGTAGTGCTTCAGTTTGAAGTTCT 
Hprt1 TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 
Utp6c TTTCGGTTGAGTTTTTCAGGA CCCTCAGGTTTACCATCTTGC 
Rplp0 CACTGGTCTAGGACCCGAGAAG GGTGCCTCTGGAGATTTTCG
Ifnb1 ATGAACAACAGGTGGATCCTCC AGGAGCTCCTGACATTTCCGAA 
Os1b GAGGTGCCGACGGAGGT TCCAGATGAAGTCTTCCCAAAG 
IRF7 CAGCGAGTGCTGTTTGGAGAC AAGTTCGTACACCTTATGCGG 
Ctnnb1 GCCACAGGATTACAAGAAGC CCACCAGAGTGAAAAGAACG 
Bcl9 AGTGCTCTCTCCAGGATATGATG GGGCAAAGAGTGTGAAATGTTG 
Csnk1d ACGCCGGGATCGAGAAGAA CCGACCGGGAATCTGTGAG 
Csnk1g2 CAAACTTCCGAGTCGGCAAGA GCTTGTAAAAGCGGTACTCCAG 
Csnk1g3 TGGGACCGAGTTTGGAGGATT CTGGCCGTCCTATTAAGAAGTTC 
Csnk2a2 TCCCGAGCTGGGGTAATCAA TGTTCCACCACGAAGGTTCTC 
Tcf7l2 CACGACAGGAGGATTCAGA GGGGCTTCTTCTTCTCTTC 
Axin2 TGACTCTCCTTCCAGATCCCA TGCCCACACTAGGCTGACA 
Gsk3b TGGCAGCAAGGTAACCACAG CGGTTCTTAAATCGCTTGTCCTG 
981 
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Table II. List of canonical Wnt/β-catenin genes whose regulatory DNA regions were 982 
identified as interacting with RVFV NSs protein during ChIP-on-chip assays (55). 983 
Gene  Chromo- NSs interacting Region Probes in p-value 984 
  some  Region Start  Length (bps) Region 985 
Apcdd1 Chr18    63078268  563  16  0.007658 986 
Axin2  Chr11  108827835  502  14  0.00618531 987 
Bcl9  Chr3    97004948  751  21  0.00823024 988 
Csnk1d Chr11  120859171  651  18  0.0033914 989 
Csnk1g2 Chr10    80096623  865  24  0.00136329 990 
Csnk1g2 Chr10    80082196  920  22  0.00671548 991 
Csnk1g3 Chr18    54109583  850  18  0.00104351 992 
Csnk1g3 Chr18    54156237  499  10  0.00828074 993 
Csnk2a2 Chr8    97965333  511  12  0.00827232 994 
Ctnnb1 Chr9  120803511  517  15  0.00766641 995 
Gsk3a  Chr7    26016588  488  14  0.00998065 996 
Gsk3b  Chr16    38213326  554  16  0.006564 997 
Kremen2 Chr17    23882003  542  14  0.00559623 998 
Lef1  Chr3  130837713  488  13  0.00916435 999 
Tcf7l2  Chr19    55894582  531  15  0.00931583 1000 
Wnt1  Chr15    98620114  407  11  0.00822183 1001 
Wnt2  Chr6    17981380  579  17  0.00595809 1002 
Wnt6  Chr1    74823318  824  23  0.00226374 1003 
Wnt6  Chr1    74830849  550  14  0.00750652 1004 
Wnt6  Chr1    74828942  494  14  0.00782631 1005 
Wnt6  Chr1    74818891  394  11  0.00812085 1006 
Wnt6  Chr1    74816494  489  13  0.00885298 1007 
Wnt8b  Chr19    44545480  754  20  0.00226374 1008 
Wnt8b  Chr19    44544618  808  23  0.00506606 1009 








